Studies that reported usage of AR with immunomodulator(s)
| First author, year of publication, location of study . | Type of study . | No. of RSV cases . | LRI-final site of infection, no. (%) . | RSV deaths/LRI, no. (%) . | Treated at URI stage . | Progression, no. (%) . | Not treated at URI stage . | Progression, no. (%) . | Treated at LRI . | Deaths, no. (%) . | Not treated at LRI . | Deaths, no. (%) . | No. of patients on this regimen . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schiffer (2009), WA7 | Retrospective | 44 | 12 (27) | 0 | 0 | 0 | 44 | 12 (27) | 3 | 0 | NA | NA | 3 AR + IVIG or RSV IVIG |
| Tsitsikas (2009), United Kingdom17 | Retrospective | 8 | 4 (50) | 0 | 4 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 8 AR + PVZ |
| Boeckh (2007), WA24 | RCT | 14 | 3 (21) | 0 | 9 | 1 (11) | 5 | 2 (40) | 3 | 0 | 0 | 0 | 3 AR + RSV IVIG |
| Chemaly (2006), TX9 * | Retrospective | 75 | 24 (32) | 4/24 (17) | 47 | 8 (17) | 34 | 16 (47) | 14 | 2 (14) | 2 | 1 (50) | 61 AR + IVIG or PVZ |
| Machado (2003), Brazil26 | Prospective | 27 | 15 (56) | 1/15 (7) | 5 | 0 | 7 | 0 | 11 | 0 | 4 | 1 (25) | 16 AR + IVIG |
| Small (2002), NY58 | Retrospective | 58 | 25 (43) | 3/25 (12) | 11 | 0 | 38 | 25 (66) | 23 | 2 (9) | 1 | 1 (100) | 23 AR + IVIG, RSV IVIG, or both |
| Boeckh (2001), WA23 | Prospective | 15 | 12 (80) | 2/12 (17) | 3 | 0 | 0 | 0 | 12 | 2 (17) | 0 | 0 | 15 AR + PVZ |
| Champlin (2001), TX14 | Retrospective | 46 | 23 (50) | 14/23 (61) | NA | NA | NA | NA | 14 | 5 (36) | 9 | 9 (100) | 14 AR + PVZ, IVIG, or RSV IVIG |
| Ljungman (2001), Sweden10 | Prospective | 46 | 27 (59) | 8/27 (30) | 2 | 0 | 10 | 0 | 5 | 2 (40) | 2 | 1 (50) | 5 AR + IVIG |
| Nichols (2001), WA1 | Retrospective | 24 | 24 (100) | 8/24 (33) | NA | NA | NA | NA | 24 | 8 (33) | 0 | 0 | 24 AR + IVIG |
| Ghosh (2000), TX29 | Prospective | 14 | 4 (29) | 2/4 (50) | 14 | 4 (29) | 0 | 0 | 4 | 2 (50) | 0 | 0 | 14 AR + IVIG |
| Whimbey (1996), TX3 | Prospective | 33 | 20 (61) | 12/20 (60) | 0 | 0 | 33 | 20 (61) | 16 | 8 (50) | 4 | 4 (100) | 16 AR + RSV IVIG |
| Fouillard (1992), France59 | Retrospective | 3 | 3 (100) | 2/3 (67) | 0 | 0 | 3 | 3 (100) | 3 | 2 (67) | 0 | 0 | 2 AR + RSV IVIG |
| Total | 407 | 196/407 (48) | 56/196 (29) | 95 | 11/95 (12) | 174 | 78/174 (45) | 136 | 33/136 (24) | 22 | 17/22 (77) |
| First author, year of publication, location of study . | Type of study . | No. of RSV cases . | LRI-final site of infection, no. (%) . | RSV deaths/LRI, no. (%) . | Treated at URI stage . | Progression, no. (%) . | Not treated at URI stage . | Progression, no. (%) . | Treated at LRI . | Deaths, no. (%) . | Not treated at LRI . | Deaths, no. (%) . | No. of patients on this regimen . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schiffer (2009), WA7 | Retrospective | 44 | 12 (27) | 0 | 0 | 0 | 44 | 12 (27) | 3 | 0 | NA | NA | 3 AR + IVIG or RSV IVIG |
| Tsitsikas (2009), United Kingdom17 | Retrospective | 8 | 4 (50) | 0 | 4 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 8 AR + PVZ |
| Boeckh (2007), WA24 | RCT | 14 | 3 (21) | 0 | 9 | 1 (11) | 5 | 2 (40) | 3 | 0 | 0 | 0 | 3 AR + RSV IVIG |
| Chemaly (2006), TX9 * | Retrospective | 75 | 24 (32) | 4/24 (17) | 47 | 8 (17) | 34 | 16 (47) | 14 | 2 (14) | 2 | 1 (50) | 61 AR + IVIG or PVZ |
| Machado (2003), Brazil26 | Prospective | 27 | 15 (56) | 1/15 (7) | 5 | 0 | 7 | 0 | 11 | 0 | 4 | 1 (25) | 16 AR + IVIG |
| Small (2002), NY58 | Retrospective | 58 | 25 (43) | 3/25 (12) | 11 | 0 | 38 | 25 (66) | 23 | 2 (9) | 1 | 1 (100) | 23 AR + IVIG, RSV IVIG, or both |
| Boeckh (2001), WA23 | Prospective | 15 | 12 (80) | 2/12 (17) | 3 | 0 | 0 | 0 | 12 | 2 (17) | 0 | 0 | 15 AR + PVZ |
| Champlin (2001), TX14 | Retrospective | 46 | 23 (50) | 14/23 (61) | NA | NA | NA | NA | 14 | 5 (36) | 9 | 9 (100) | 14 AR + PVZ, IVIG, or RSV IVIG |
| Ljungman (2001), Sweden10 | Prospective | 46 | 27 (59) | 8/27 (30) | 2 | 0 | 10 | 0 | 5 | 2 (40) | 2 | 1 (50) | 5 AR + IVIG |
| Nichols (2001), WA1 | Retrospective | 24 | 24 (100) | 8/24 (33) | NA | NA | NA | NA | 24 | 8 (33) | 0 | 0 | 24 AR + IVIG |
| Ghosh (2000), TX29 | Prospective | 14 | 4 (29) | 2/4 (50) | 14 | 4 (29) | 0 | 0 | 4 | 2 (50) | 0 | 0 | 14 AR + IVIG |
| Whimbey (1996), TX3 | Prospective | 33 | 20 (61) | 12/20 (60) | 0 | 0 | 33 | 20 (61) | 16 | 8 (50) | 4 | 4 (100) | 16 AR + RSV IVIG |
| Fouillard (1992), France59 | Retrospective | 3 | 3 (100) | 2/3 (67) | 0 | 0 | 3 | 3 (100) | 3 | 2 (67) | 0 | 0 | 2 AR + RSV IVIG |
| Total | 407 | 196/407 (48) | 56/196 (29) | 95 | 11/95 (12) | 174 | 78/174 (45) | 136 | 33/136 (24) | 22 | 17/22 (77) |
RCT indicates randomized controlled studies; and NA, not available.
Data on specific therapy and outcome for HSCT recipients were extracted from the available database maintained by the authors.